Artie Suckow, DTx Pharma CEO
July 17, 2023 11:30 AM EDTUpdated 12:23 PM
Deals
R&D

No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

Tyler Patchen

News Reporter

No­var­tis will con­tin­ue to add siR­NA ca­pa­bil­i­ties to its tool belt in a deal worth up to $1 bil­lion.

The Swiss phar­ma

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times